18762934

Source:http://linkedlifedata.com/resource/pubmed/id/18762934

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists.
Subject	Predicate	Object	Context
pubmed-article:18762934	rdf:type	pubmed:Citation	lld:pubmed
pubmed-article:18762934	lifeskim:mentions	umls-concept:C0008976	lld:lifeskim
pubmed-article:18762934	lifeskim:mentions	umls-concept:C0003191	lld:lifeskim
pubmed-article:18762934	lifeskim:mentions	umls-concept:C2349209	lld:lifeskim
pubmed-article:18762934	lifeskim:mentions	umls-concept:C1549649	lld:lifeskim
pubmed-article:18762934	pubmed:issue	1	lld:pubmed
pubmed-article:18762934	pubmed:dateCreated	2008-12-18	lld:pubmed
pubmed-article:18762934	pubmed:abstractText	This paper assesses the design of clinical studies used in the process of regulatory approval, focusing on how add-on studies affect regulatory decisions.	lld:pubmed
pubmed-article:18762934	pubmed:language	eng	lld:pubmed
pubmed-article:18762934	pubmed:journal	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:18762934	pubmed:citationSubset	IM	lld:pubmed
pubmed-article:18762934	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:18762934	pubmed:status	MEDLINE	lld:pubmed
pubmed-article:18762934	pubmed:month	Jan	lld:pubmed
pubmed-article:18762934	pubmed:issn	1432-1041	lld:pubmed
pubmed-article:18762934	pubmed:author	pubmed-author:GarattiniSilv...	lld:pubmed
pubmed-article:18762934	pubmed:author	pubmed-author:Bertele'Vitto...	lld:pubmed
pubmed-article:18762934	pubmed:author	pubmed-author:OttolenghiLau...	lld:pubmed
pubmed-article:18762934	pubmed:issnType	Electronic	lld:pubmed
pubmed-article:18762934	pubmed:volume	65	lld:pubmed
pubmed-article:18762934	pubmed:owner	NLM	lld:pubmed
pubmed-article:18762934	pubmed:authorsComplete	Y	lld:pubmed
pubmed-article:18762934	pubmed:pagination	33-41	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:meshHeading	pubmed-meshheading:18762934...	lld:pubmed
pubmed-article:18762934	pubmed:year	2009	lld:pubmed
pubmed-article:18762934	pubmed:articleTitle	Limits of add-on trials: antirheumatic drugs.	lld:pubmed
pubmed-article:18762934	pubmed:affiliation	Laboratory of Regulatory Policies, Mario Negri Institute for Pharmacological Research, Via Giuseppe La Masa 19, 20156 Milan, Italy.	lld:pubmed
pubmed-article:18762934	pubmed:publicationType	Journal Article	lld:pubmed
pubmed-article:18762934	pubmed:publicationType	Review	lld:pubmed